Biopharmaceutical company PTC Therapeutics Inc (NASDAQ: PTCT) announced on Tuesday that it has submitted a New Drug Application (NDA) for sepiapterin to the US Food and Drug Administration (FDA).
This NDA is for the treatment of paediatric and adult patients with phenylketonuria (PKU), a rare but serious inherited disorder, including the full spectrum of ages and disease subtypes.
The company said that the submission is based on the highly statistically significant and clinically meaningful results from the phase 3 APHENITY trial that demonstrated a mean reduction in Phe levels of 63% in the overall treated population, and 69% in the subgroup of patients with classical PKU. The NDA also includes data from the APHENITY open-label extension study providing evidence of sepiapterin's durability of effect and data from the Phe tolerance sub-study.
Matthew B Klein, MD, PTC Therapeutics' chief executive officer, said: "This NDA submission is an important step in bringing this therapy to children and adults living with PKU in the US. The robust sepiapterin clinical trial data, including Phe tolerance results, support the potential of sepiapterin to meet the persistent unmet medical need for the large number of children and adults with PKU."
NeuroTherapia's Phase 2 Alzheimer's disease trial receives European regulatory approval
Syndax Pharmaceuticals grants share purchase inducement awards to six new employees
Hippo Pharmacy launches fast, free delivery on orders over USD150
Polarean Imaging expands reach with Taiwanese distribution deal
AstraZeneca secures EU recommendation for Imfinzi in limited-stage small cell lung cancer
CHMP recommends EU approval of Daiichi Sankyo and AstraZeneca's datopotamab deruxtecan
Renalys Pharma completes patient enrolment for Phase III clinical trial of sparsentan
NICE recommends ALK's ACARIZAX for house dust mite allergic rhinitis treatment in UK's NHS
Roche's blood test measuring Lp(a) in molar units receives US FDA 510(k) approval
Breckenridge Pharmaceutical's Everolimus Tablets for Oral Suspension receive US FDA approval
Amgen's BLINCYTO (blinatumomab) monotherapy approved in Europe
HeartBeam submits FDA 510(k) application for groundbreaking 12-lead ECG synthesis software
FDA grants Vicore Pharma Fast Track Designation for buloxibutid in idiopathic pulmonary fibrosis
FDA accepts Saol Therapeutics' SL1009 New Drug Application for Priority Review